Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.
This study investigated the treatment of anaplastic oligodendroglial tumors across nine Korean institutions. We reviewed the medical records from 381 patients with histologically confirmed anaplastic oligodendroglioma or anaplastic oligoastrocytoma (AOA) from 2000 to 2010. Clinical factors and treatment patterns were analyzed for each year. Post-operative therapy was performed in 354 patients (94.1 %), of which 133 received radiotherapy (RT) alone and 189 received both RT and chemotherapy. RT alone was the preferred treatment toward the end of the study period (29.4 % in 2000-2001 vs. 56.3 % in 2010, P = 0.005). The use of procarbazine, lomustine, and vincristine (PCV) decreased (57.6 % in 2000-2001 vs. 28.6 % in 2010, P = 0.001) and the use of temozolomide (TMZ) increased (0 % in 2000-2001 vs. 61.9 % in 2010, P < 0.001) over the study period. A combination of chemotherapy and RT was used more often than RT alone in young patients (P = 0.036) and patients with a good performance status (P = 0.023). The 1p/19q co-deletion status and O-6-methyguanine-DNA methyltransferase methylation were analyzed since 2004 but were not significant factors for determining whether to administer chemotherapy. Among the patients who received chemotherapy, TMZ was used more often in patients with AOA (P = 0.007) and PCV was used more often in patients with either multiple lesions (P = 0.027) or the 1p/19q co-deletion (P = 0.026). Our results demonstrate that the treatment pattern for oligodendroglial tumors changed significantly across the study period. In particular, TMZ has replaced PCV, and the use of molecular markers as well as RT alone has increased, but a unified protocol remains to be established.
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Tosol
T
Yu
Hyun-Cheol
HC
Kang
Do Hoon
DH
Lim
Il Han
IH
Kim
Woong-Ki
WK
Chung
Chang-Ok
CO
Suh
Byung Ock
BO
Choi
Kwan Ho
KH
Cho
Jae Ho
JH
Cho
Jin Hee
JH
Kim
Chul-Kee
CK
Park
Yong-Kil
YK
Hong
In Ah
IA
Kim
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy / Q000639:trends*; D005260:Female; D006801:Humans; D007723:Korea; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures; D009837:Oligodendroglioma / Q000628:therapy*; D011878:Radiotherapy / Q000639:trends; D055815:Young Adult
D000970:Antineoplastic Agents